Melanotan II

Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH) — a naturally occurring peptide hormone. It is one of the most studied molecules in melanocortin research, and its scientific story is more consequential than most peptides in this library: a compound derived from it became an FDA-approved drug.

What you’re reading about

Melanotan II (often shortened to MT-2) is a non-selective melanocortin receptor agonist — meaning it activates several receptors in the family at once, which is why its research spans such different areas, from pigmentation to appetite to sexual function.

Mechanism under investigation

The melanocortin system runs on five receptors, and Melanotan II engages several:

• MC1R — found on melanocytes; drives melanin synthesis and pigmentation.
• MC3R / MC4R — central receptors involved in appetite, energy balance, and sexual arousal pathways.
• MC5R — associated with exocrine gland function.

This breadth is both the interest and the challenge: a single molecule touching several receptor subtypes produces a wide range of effects, which is exactly what drove the development of more selective successors.

Research applications

• Melanogenesis and photoprotection research via MC1R.
• Appetite and energy-balance signaling via MC4R.
• Neuroendocrine and sexual-function pathways.
• Structure-activity work aimed at building receptor-selective analogs.

Clinical outlook

This is where melanocortin research becomes genuinely notable. Melanotan II itself is in active human study — a Phase 2 trial is recruiting to evaluate it as an adjunct to NB-UVB phototherapy (NCT07437560). More importantly, the wider class has already crossed the finish line: bremelanotide, a melanocortin agonist developed out of Melanotan II research, completed Phase 3 trials (NCT02333071, NCT02338960) and was approved by the FDA in 2019. Separately, afamelanotide — another α-MSH analog — was approved for erythropoietic protoporphyria after its own Phase 2/3 program (NCT01097044). Few research peptides can point to two approved drugs emerging from their pharmacology; that is the strongest possible argument for continued melanocortin investigation.